• By ICR Secretariat
  • Posted Monday, June 6, 2022

Thousands to potentially benefit from Roche treatment for sight loss

https://www.pharmatimes.com/news/thousands_to_potentially_benefit_from_roche_treatment_for_sight_loss_1449327

The National Institute for Health and Care Excellence (NICE) has recommended Roche’s faricimab (Vabysmo) as a treatment option for two leading forms of sight loss. Faricimab, an eye injection, is recommended for adults with wet age-related macular degeneration (AMD) or diabetic macular oedema (DMO).